Background: Electronic medication monitors (EMMs) are associated with decreased rescue inhaler use, symptom burden, and increased medication adherence in asthma. However, the use of EMMs in people with chronic obstructive pulmonary disease (COPD) using the ELLIPTA dry powder inhaler has not been studied. Methods: This was an open-label, single-arm, prospective observational study of EMMs and associated application (app) use over 12 weeks and up to 24 weeks (April-October 2019) in people with self-reported COPD aged ≥40 years enrolled in the COPD Patient-Powered Research Network, using an ELLIPTA inhaler. The primary outcome was daily active use of the app over 12 weeks. Treatment adherence, rescue inhaler use, and participant satisfaction were assessed over the same period. Results: Among the 122 participants, mean (standard deviation [SD]) proportion of days participants opened the app was 59.5% (31.4), 51.1% (33.5) and 41.3% (34.2) for Days 1-30, 31-60 and 61-90, respectively. Mean (SD) adherence to maintenance medication remained stable: 80.2% (22.7) and 79.9% (26.7) for Days 1-30 and 61-90, respectively. In participants using a rescue inhaler and EMM, mean (SD) rescue-free days increased from 18.5 (10.0; Days 1-30, n=51) to 21.4 (9.6; Days 61-90, n=48). Participants reported high levels of confidence in using the EMM, valued app reminders highly, and reported high system satisfaction (mean [SD] scale: 1=low, 5=high; 4.6 [1.1], 4.3 [1.1] and 4.1 [1.1], respectively). Conclusions: Use of an ELLIPTA EMM with frequent app engagement, high participant satisfaction, and decreased rescue medication use may aid COPD management.
|Number of pages||14|
|Journal||Chronic Obstructive Pulmonary Diseases|
|State||Published - 2021|
Bibliographical noteFunding Information:
Abbreviations: electronic medication monitor, EMM; chronic obstructive pulmonary disease, COPD; standard deviation, SD; application, app; ELLIPTA EMM Experience in COPD, ESSENCE; Propeller Health, PH; Patient-Powered Research Network, PPRN; metered-dose inhaler, MDI; COPD Assessment Test, CAT; Global initiative for chronic Obstructive Lung Disease, GOLD; modified COPD treatment ratio, mCTR; body mass index, BMI Funding Support: This study was funded by GlaxoSmithKline plc., (HO-18-19715/210024); the study used electronic medication monitors/app provided by Propeller Health. Date of Acceptance: August 31, 2021 | Published Online Date: September 10, 2021 Citation: Yawn BP, McCreary GM, Linnell JA, et al. Pilot study of a patient experience with an ELLIPTA inhaler electronic medication monitor and associated integrated system: a prospective observational study using the COPD Patient-Powered Research Network. Chronic Obstr Pulm Dis. 2021;8(4):488-501. doi: https://doi.org/10.15326/jcopdf.2021.0218
© 2021 COPD Foundation. All rights reserved.
- Chronic obstructive pulmonary disease
- Dry powder inhaler
- Electronic medication monitor
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine